AMZN
Amazon.com, Inc.
AMZN has the edge over CALY overall, supported by lower modeled downside and stronger valuation.
CALY
Callaway Golf Company
CALY trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CALY Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| Strong | |
| Strong |
CALY's cash flow and balance sheet are currently strong, and its profitability is stable, but its revenue is weak.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
CALY PE Valuation
CALY has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CALY on the outlook, with more favorable revenue expectations.
CALY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CALY's earnings to grow and its profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CALY on earnings quality, reporting a profit while its opponent remains loss making.
CALY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.98 | — |
| Q3 2026 | -$1.15 | +$7.03 |
| Q2 2026 | -$1.48 | +$6.64 |
| Q1 2026 | -$1.77 | +$6.14 |
| Q4 2025 | -$2.23 | +$5.65 |
| Q3 2025 | -$8.18 | -$8.14 |
| Q2 2025 | -$8.12 | -5900% |
| Q1 2025 | -$7.91 | -2029% |
| Q4 2024 | -$7.88 | -1676% |
CALY is still losing money, but far less than before: $1.15 per share over the past year, against $8.18 at its worst in late 2025.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CALY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over CALY on profitability, with a higher operating margin.
CALY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $436.9M | -53% |
| Q2 2026 | $612.2M | -45% |
| Q1 2026 | $687.5M | -37% |
| Q4 2025 | $367.5M | -60% |
| Q3 2025 | $934M | -7.8% |
| Q2 2025 | $1.1B | -4.1% |
| Q1 2025 | $1.1B | -4.5% |
| Q4 2024 | $924.4M | +3% |
CALY's revenue has slid since its 2023 peak: $437M last quarter, down 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +7.2 points |
| Q2 2026 | 19% | +9.2 points |
| Q1 2026 | 20% | +14 points |
| Q4 2025 | -15% | +143 points |
| Q3 2025 | 3% | -0.3 points |
| Q2 2025 | 9.5% | +0.6 points |
| Q1 2025 | 6.1% | +0.2 points |
| Q4 2024 | -158% | -154 points |
CALY's operating margin was 10% last quarter, up 7.2 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CALY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $180.8M | +12% |
| Q2 2026 | $238.1M | +354% |
| Q1 2026 | -$176M | -$20.9M |
| Q4 2025 | $242.7M | +$267.7M |
| Q3 2025 | $162.1M | +48% |
| Q2 2025 | $52.5M | -63% |
| Q1 2025 | -$155.1M | -$16.4M |
| Q4 2024 | -$25M | -157% |
CALY has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CALY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.6% | -6.8M shares |
| 1 year | -0.3% | -600K shares |
| 3 years | -8.9% | -17.9M shares |
| 5 years | -1.4% | -2.7M shares |
| Available history | +90% | +87M shares |
CALY has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $50.7M |
| Q2 2026 | $42.5M |
| Q1 2026 | $42M |
| Q4 2025 | $300,000 |
| Q3 2025 | $100,000 |
| Q2 2025 | — |
| Q1 2025 | $3.3M |
| Q4 2024 | — |
CALY spent $136M buying back its own shares over the past year, more than ten times what it spent the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CALY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.2x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 2.9x | Moderate |
| Q3 2024 | 2.5x | Moderate |
| Q2 2024 | 2.6x | Moderate |
| Q1 2024 | 2.9x | Moderate |
| Q4 2023 | 2.5x | Moderate |
CALY has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CALY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 51.0 | Neutral |
CALY's weekly RSI is 56 (neutral) and its Stochastic is 51 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CALY PE vs Consumer Cyclical Sector
| Metric | CALY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CALY has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
CALY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.9 | 11% above |
| 20 week MA | $16.2 | 2.5% above |
| 50 week MA | $15.1 | 9.5% above |
| 100 week MA | $11.7 | 42% above |
| 200 week MA | $13.6 | 22% above |
CALY has climbed back above all five of its weekly moving averages, and it's now 22% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has finished higher in five of the last six years, two of them by more than 50%. It's up 15% so far in 2026.
CALY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.9 | $24.4 | +17% |
| 2021 | $24.4 | $27.0 | +11% |
| 2022 | $27.0 | $19.7 | -27% |
| 2023 | $19.7 | $14.3 | -27% |
| 2024 | $14.3 | $7.72 | -46% |
| 2025 | $7.72 | $11.7 | +52% |
| 2026 YTD | $11.7 | $16.6 | +41% |
CALY has the edge over AMZN on returns for 2026, with the stronger performance.